FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750924434> ?p ?o ?g. }

• W2750924434 endingPage "685.e5" @default.
• W2750924434 startingPage "685.e1" @default.
• W2750924434 abstract "Background The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks’ gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks’ gestation. Preterm preeclampsia with delivery at <37 weeks’ gestation, which was the primary outcome, occurred in 1.6% (13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74). Objective We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. Study Design This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of <90% and ≥90%, after adjustment for the estimated risk of preterm preeclampsia at screening and the participating center. The choice of cut-off of 90% was based on an exploratory analysis of the treatment effect. Logistic regression analysis was used to investigate predictors of compliance ≥90% among maternal characteristics and medical history. Results Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance <90%, in 22/588 (3.7%) of participants in the placebo group with compliance ≥90%, and in 13/234 (5.6%) of participants in the placebo group with compliance <90%. The odds ratio in the aspirin group for preterm preeclampsia was 0.24 (95% confidence interval, 0.09–0.65) for compliance ≥90% and 0.59 (95% confidence interval, 0.23–1.53) for compliance <90%. Compliance was positively associated with family history of preeclampsia and negatively associated with smoking, maternal age <25 years, Afro-Caribbean and South Asian racial origin, and history of preeclampsia in a previous pregnancy. Conclusion The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance. The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies. Screening was carried out at 11-13 weeks’ gestation with an algorithm that combines maternal factors and biomarkers (mean arterial pressure, uterine artery pulsatility index, and maternal serum pregnancy-associated plasma protein A and placental growth factor). Those with an estimated risk for preterm preeclampsia of >1 in 100 were invited to participate in a double-blind trial of aspirin (150 mg/d) vs placebo from 11-14 until 36 weeks’ gestation. Preterm preeclampsia with delivery at <37 weeks’ gestation, which was the primary outcome, occurred in 1.6% (13/798) participants in the aspirin group, as compared with 4.3% (35/822) in the placebo group (odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74). We sought to examine the influence of compliance on the beneficial effect of aspirin in prevention of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial. This was a secondary analysis of data from the trial. The proportion of prescribed tablets taken was used as an overall measure of compliance. Logistic regression analysis was used to estimate the effect of aspirin on the incidence of preterm preeclampsia according to compliance of <90% and ≥90%, after adjustment for the estimated risk of preterm preeclampsia at screening and the participating center. The choice of cut-off of 90% was based on an exploratory analysis of the treatment effect. Logistic regression analysis was used to investigate predictors of compliance ≥90% among maternal characteristics and medical history. Preterm preeclampsia occurred in 5/555 (0.9%) participants in the aspirin group with compliance ≥90%, in 8/243 (3.3%) of participants in the aspirin group with compliance <90%, in 22/588 (3.7%) of participants in the placebo group with compliance ≥90%, and in 13/234 (5.6%) of participants in the placebo group with compliance <90%. The odds ratio in the aspirin group for preterm preeclampsia was 0.24 (95% confidence interval, 0.09–0.65) for compliance ≥90% and 0.59 (95% confidence interval, 0.23–1.53) for compliance <90%. Compliance was positively associated with family history of preeclampsia and negatively associated with smoking, maternal age <25 years, Afro-Caribbean and South Asian racial origin, and history of preeclampsia in a previous pregnancy. The beneficial effect of aspirin in the prevention of preterm preeclampsia appears to depend on compliance." @default.
• W2750924434 created "2017-09-15" @default.
• W2750924434 creator A5009418408 @default.
• W2750924434 creator A5009712176 @default.
• W2750924434 creator A5010923035 @default.
• W2750924434 creator A5016652536 @default.
• W2750924434 creator A5017751301 @default.
• W2750924434 creator A5020409731 @default.
• W2750924434 creator A5023475823 @default.
• W2750924434 creator A5026094164 @default.
• W2750924434 creator A5039615761 @default.
• W2750924434 creator A5040759889 @default.
• W2750924434 creator A5041779212 @default.
• W2750924434 creator A5055953235 @default.
• W2750924434 creator A5072511800 @default.
• W2750924434 creator A5080220991 @default.
• W2750924434 creator A5087922313 @default.
• W2750924434 date "2017-12-01" @default.
• W2750924434 modified "2023-10-18" @default.
• W2750924434 title "Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia" @default.
• W2750924434 cites W1492212171 @default.
• W2750924434 cites W1525863247 @default.
• W2750924434 cites W1540530901 @default.
• W2750924434 cites W1597497013 @default.
• W2750924434 cites W1975775758 @default.
• W2750924434 cites W1979872571 @default.
• W2750924434 cites W2080542014 @default.
• W2750924434 cites W2094438867 @default.
• W2750924434 cites W2108882651 @default.
• W2750924434 cites W2130645342 @default.
• W2750924434 cites W2132181466 @default.
• W2750924434 cites W2139727491 @default.
• W2750924434 cites W2147982456 @default.
• W2750924434 cites W2171322051 @default.
• W2750924434 cites W2288806715 @default.
• W2750924434 cites W2520664488 @default.
• W2750924434 cites W2548103122 @default.
• W2750924434 cites W2583501307 @default.
• W2750924434 cites W2625297718 @default.
• W2750924434 cites W2730504020 @default.
• W2750924434 cites W4230501493 @default.
• W2750924434 cites W4242472190 @default.
• W2750924434 doi "https://doi.org/10.1016/j.ajog.2017.08.110" @default.
• W2750924434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28888591" @default.
• W2750924434 hasPublicationYear "2017" @default.
• W2750924434 type Work @default.
• W2750924434 sameAs 2750924434 @default.
• W2750924434 citedByCount "88" @default.
• W2750924434 countsByYear W27509244342017 @default.
• W2750924434 countsByYear W27509244342018 @default.
• W2750924434 countsByYear W27509244342019 @default.
• W2750924434 countsByYear W27509244342020 @default.
• W2750924434 countsByYear W27509244342021 @default.
• W2750924434 countsByYear W27509244342022 @default.
• W2750924434 countsByYear W27509244342023 @default.
• W2750924434 crossrefType "journal-article" @default.
• W2750924434 hasAuthorship W2750924434A5009418408 @default.
• W2750924434 hasAuthorship W2750924434A5009712176 @default.
• W2750924434 hasAuthorship W2750924434A5010923035 @default.
• W2750924434 hasAuthorship W2750924434A5016652536 @default.
• W2750924434 hasAuthorship W2750924434A5017751301 @default.
• W2750924434 hasAuthorship W2750924434A5020409731 @default.
• W2750924434 hasAuthorship W2750924434A5023475823 @default.
• W2750924434 hasAuthorship W2750924434A5026094164 @default.
• W2750924434 hasAuthorship W2750924434A5039615761 @default.
• W2750924434 hasAuthorship W2750924434A5040759889 @default.
• W2750924434 hasAuthorship W2750924434A5041779212 @default.
• W2750924434 hasAuthorship W2750924434A5055953235 @default.
• W2750924434 hasAuthorship W2750924434A5072511800 @default.
• W2750924434 hasAuthorship W2750924434A5080220991 @default.
• W2750924434 hasAuthorship W2750924434A5087922313 @default.
• W2750924434 hasBestOaLocation W27509244342 @default.
• W2750924434 hasConcept C126322002 @default.
• W2750924434 hasConcept C131872663 @default.
• W2750924434 hasConcept C142724271 @default.
• W2750924434 hasConcept C151956035 @default.
• W2750924434 hasConcept C156957248 @default.
• W2750924434 hasConcept C168563851 @default.
• W2750924434 hasConcept C204787440 @default.
• W2750924434 hasConcept C27081682 @default.
• W2750924434 hasConcept C2777218350 @default.
• W2750924434 hasConcept C2777628954 @default.
• W2750924434 hasConcept C2779234561 @default.
• W2750924434 hasConcept C44249647 @default.
• W2750924434 hasConcept C46973012 @default.
• W2750924434 hasConcept C50440223 @default.
• W2750924434 hasConcept C54355233 @default.
• W2750924434 hasConcept C71924100 @default.
• W2750924434 hasConcept C86803240 @default.
• W2750924434 hasConceptScore W2750924434C126322002 @default.
• W2750924434 hasConceptScore W2750924434C131872663 @default.
• W2750924434 hasConceptScore W2750924434C142724271 @default.
• W2750924434 hasConceptScore W2750924434C151956035 @default.
• W2750924434 hasConceptScore W2750924434C156957248 @default.
• W2750924434 hasConceptScore W2750924434C168563851 @default.
• W2750924434 hasConceptScore W2750924434C204787440 @default.
• W2750924434 hasConceptScore W2750924434C27081682 @default.
• W2750924434 hasConceptScore W2750924434C2777218350 @default.

• next